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Abstract: The association between nonalcoholic fatty liver disease (NAFLD) and chronic kidney
disease has attracted interest and attention over recent years. However, no data are available in
children. We determined whether children with NAFLD show signs of renal functional alterations,
as determined by estimated glomerular filtration rate (eGFR) and urinary albumin excretion.
We studied 596 children with overweight/obesity, 268 with NAFLD (hepatic fat fraction ě5% on
magnetic resonance imaging) and 328 without NAFLD, and 130 healthy normal-weight controls.
Decreased GFR was defined as eGFR < 90 mL/min/1.73 m2. Abnormal albuminuria was defined as
urinary excretion of ě30 mg/24 h of albumin. A greater prevalence of eGFR < 90 mL/min/1.73 m2
was observed in patients with NAFLD compared to those without liver involvement and healthy
subjects (17.5% vs. 6.7% vs. 0.77%; p < 0.0001). The proportion of children with abnormal albuminuria
was also higher in the NAFLD group compared to those without NAFLD, and controls (9.3% vs. 4.0%
vs. 0; p < 0.0001). Multivariate logistic regression analysis revealed that NAFLD was associated with
decreased eGFR and/or microalbuminuria (odds ratio, 2.54 (confidence interval, 1.16–5.57); p < 0.05)
independently of anthropometric and clinical variables. Children with NAFLD are at risk for early
renal dysfunction. Recognition of this abnormality in the young may help to prevent the ongoing
development of the disease.
Keywords: nonalcoholic fatty liver disease; renal function; obesity; children
1. Introduction
Concurrent with the epidemic of obesity across the world, nonalcoholic fatty liver disease
(NAFLD) is becoming one of the most prevalent chronic liver disorders in both adults and children.
It is now known that NAFLD is not only a risk factor for hepatic failure and hepatic carcinoma, but it
is also associated with a spectrum of extrahepatic diseases generally linked to metabolic syndrome
(MetS) such as type 2 diabetes, and cardiovascular disease [1,2]. Recent studies in the pediatric
obese population have demonstrated that the prevalence of prediabetes and MetS is significantly
increased in subjects with increased hepatic fat content, and that liver steatosis, independently of
visceral and intramyocellular lipid content, is a key determinant of the impairment of liver, muscle,
and adipose insulin sensitivity [3,4]. Several studies have reported associations between NAFLD and
Int. J. Mol. Sci. 2016, 17, 1218; doi:10.3390/ijms17081218 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2016, 17, 1218 2 of 10
subclinical atherosclerosis and between NAFLD and cardiac function alterations, independently of
established risk factors [5–7]. In addition, emerging evidence suggests that subjects with NAFLD have
an increased risk of chronic kidney disease (CKD), defined by a decline in the estimated glomerular
filtration rate (eGFR) and/or microalbuminuria and/or overt proteinuria [8–12]. However, no data are
available in children regarding a possible association between NAFLD and impaired renal function.
Recognition of the influence of NAFLD on renal function in the early age would enable us to better
understand the association of NAFLD and CKD, since there is less potential for confusion with
adult-onset complications.
Thus, in this study we sought to determine whether children with overweight/obesity and
NAFLD show signs of renal functional alterations, as assessed by eGFR and urinary albumin
excretion, compared to children with overweight/obesity but without NAFLD as well as to healthy
normal-weight controls.
2. Results
2.1. Clinical and Laboratory Data from the Study Population
Clinical and laboratory data from the study population are presented in Table 1. None of the
enrollees had type 2 diabetes mellitus. Patients with NAFLD were on average older than those without
NAFLD and healthy controls, and had higher waist circumference (WC) as well as higher values
for systolic and diastolic blood pressure (BP), higher triglycerides, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), uric acid, fasting glucose, insulin levels and homeostasis model
assessment of insulin resistance (HOMA-IR) values, and lower high-density lipoprotein-cholesterol
(HDL-C) concentrations. Patients with NAFLD had significantly lower whole-body insulin sensitivity
index (WBISI) than those without NAFLD. Obese children with NAFLD and obese subjects without
NAFLD had significantly higher eGFR compared to healthy controls (median, 115 (interquartile range,
104–134) and 115 (96–132) vs. 108 (100–118) mL/min/1.73 m2; p < 0.0001), whereas no differences
were found between patients with and without NAFLD. However, a greater frequency of reduced
eGFR (<90 mL/min/1.73 m2) was observed in obese subjects with NAFLD compared to obese children
without liver involvement and healthy controls (17.5% vs. 6.7% vs. 0.77%, respectively; p < 0.0001).
The proportion of children with microalbuminuria was also higher in the NAFLD group compared to
obese children without liver involvement and healthy controls (9.3% vs. 4.0% vs. 0; p < 0.0001). None of
the participants had eGFR < 60 mL/min/1.73 m2 or macroalbuminuria. Compared to healthy controls,
the prevalence of hyperfiltration was higher in the obese cohort, regardless of liver involvement
(Table 1).
To analyze the variables associated with decreased eGFR and/or microalbuminuria, we performed
a logistic regression analysis in the cohort of subjects with overweight/obesity. NAFLD (odds ratio
(OR), 2.34; 95% confidence interval (CI), 1.31–4.16; p < 0.01) was associated with abnormal renal
function independently of age, gender, and pubertal status. After further adjustment for body mass
index-standard deviation (BMI-SD) score, WC, hypertension, low HDL-C values, elevated triglycerides,
and glucose impairment, results did not substantially change (Table 2).
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Table 1. Clinical and laboratory characteristics of the study population.
Normal Weight NO NAFLD NAFLD p Value *
No. patients 130 328 268 <0.0001
Age, years 10.6 (3.5) 10.1 (2.9) 11.2 (2.9) d <0.0001
Male sex, n (%) 61 (46.9) 151 (46.0) 166 (61.9) a,d <0.0001
BMI-SD score 0.17 (0.85) 1.85 (0.45) a 2.0 (0.45) a,d <0.0001
Waist circumference, cm 65 (10) 82 (12) a 92 (13) a,d <0.0001
Systolic BP, mmHg 102 (11) 107 (12) b 114 (12) a,d <0.0001
Diastolic BP, mmHg 63 (7) 65 (9) c 69 (8) a,d <0.0001
Total cholesterol, mg/dL 166 (145–186) 161 (139–187) 159 (137–181) 0.077
LDL-C 92 (72–118) 94 (76–115) 94 (74–111) 0.78
HDL-C, mg/dL 56 (50–83) 51 (44–60) a 46 (38–53) a,d <0.0001
Triglycerides, mg/dL 62 (50–83) 70 (50–99) 89 (58–127) a,d <0.0001
AST, U/L 22 (20–30) 23 (20–27) c 26 (21–35) a,d <0.0001
ALT, U/L 16 (13–20) 18 (14–23) b 31 (19–54) a,d <0.0001
Uric acid 0.21 (0.18–0.25) 0.25 (0.22–0.29) a 0.28 (0.24–0.34) a,d <0.0001
Glucose, mg/dL 83 (7) 83 (7) 85 (11) 0.002
Insulin, µU/mL 7.5 (4.3–10.5) 11.1 (7.5–15.4) a 15.2 (10.1–23.2) a,d <0.0001
HOMA-IR 1.58 (0.90–2.20) 2.30 (1.55–3.22) a 3.23 (2.05–5.0) a,d <0.0001
WBISI - 6.5 (4.5–9.0) 3.5 (2.4–5.6) d -
eGFR, mL/min/1.73 m2 108 (100–118) 115 (104–134) a 115 (96–132) a <0.0001
eGFR < 90 mL/min/1.73 m2, n (%) 1 (0.77) 22 (6.7) b 47 (17.5) a,d <0.0001
eGFR > 139 mL/min/1.73 m2, n (%) 6 (4.6) 56 (17.0) a 46 (17.2) a 0.002
Microalbuminuria, n (%) 0 13 (4.0) a 25 (9.3) a,d <0.0001
Results are expressed as n (%), mean (standard devation), or median (interquartile ranges). * Anova or Kruskal-Wallis test; a p < 0.0001; b p < 0.01; c p < 0.05 vs. controls; d p < 0.0001
vs. obese children without NAFLD; NAFLD, nonalcoholic fatty liver disease; BMI-SD score, Body mass index- standard deviation score; BP, Blood pressure; LDL-C, Low density
lipoprotein-cholesterol; HDL-C, High-density lipoprotein-cholesterol; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; HOMA-IR, Homeostasis model assessment of
insulin resistance; WBISI, Whole-body insulin sensitivity index; eGFR, estimated glomerular filtration rate.
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Table 2. Associations of NAFLD with eGFR < 90 mL/min/1.73 m2 and/or microalbuminuria in children with overweight/obesity.
Variables Odds Ratio (95% CI) p Value
Adjusted model 1: age, gender, pubertal status 2.34 (1.31–4.16) 0.004
Adjusted model 2: model 1 plus BMI-SD score, WC, High BP, High TG, low HDL-C, and high FG 2.54 (1.16–5.57) 0.02
Adjusted model 3: model 1 plus BMI-SD score, WC, High BP, High TG, low HDL-C, and IR 2.30 (1.02–5.17) 0.04
CI, confidence interval; eGFR, estimated glomerular filtration rate; BMI-SD score, Body mass index- standard deviation score; WC, waist circumference; BP, Blood pressure;
TG, triglycerides; HDL-C, High-density lipoprotein-cholesterol; FG, fasting glucose; IR, insulin resistance.
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2.2. Findings in Children with Biopsy-Proven Nonalcoholic Fatty Liver Disease (NAFLD)
To investigate the association of renal dysfunction further with advanced stages of NAFLD such
as steatohepatitis (NASH), we analysed the data obtained in the small subgroup of 41 patients who
underwent liver biopsy. Definite-NASH was diagnosed in 26 (63.4%) children, while not-NASH in
15 (36.5%). Compared to children without NASH, those with NASH had significantly lower eGFR
(median, 88 (83–107) vs. 123 (110–130) mL/min/1.73 m2; p < 0.01). In addition, more children with
NASH had eGFR of <90 mL/min/1.73 m2 and/or microalbuminuria than those without NASH (17/26
(65.4%) vs. 6/15 (40.0%); p < 0.01).
3. Discussion
Early recognition of impaired renal function, in particular reduced GFR, is crucial to prevent
serious complications [13]. Large epidemiologic studies have found a robust relationship between
obesity and risk for CKD [14–16]. In a community-based sample of 2585 adult individuals with renal
disease at baseline and a mean follow-up of 18.5 years, BMI was reported to determine a significant
increase in the odds of developing kidney disease by 23% (OR, 1.23; 95% CI, 1.08–1.41) per standard
deviation unit [14]. In 9685 adults participating to the Hypertension Detection and Follow-Up Program,
free of CKD at baseline, the incidence of CKD was 28%, 31%, and 34%, respectively, in the ideal body
mass index, overweight, and obese groups, after a follow-up of five years [15]. After adjustment
for variables, such as age, gender, race, diabetes mellitus, mean baseline diastolic BP, and slope
of diastolic BP, at baseline both overweight (OR, 1.21; 95% CI, 1.05 to 1.41) and obesity (OR, 1.40;
95% CI, 1.20 to 1.63) were associated with increased incident CKD odds at year 5 [15]. In addition,
a retrospective cohort study of 320,252 adults, who were followed for 15 to 35 years, showed that a
high BMI (ě25.0 kg/m2) determined who is at high risk of developing end-stage renal disease [16].
Taken together, these studies indicate that higher BMI in adults is a risk factor for the development of
new onset kidney disease. Several possible pathophysiologic pathways may underlie this association.
One possibility is that particular characteristics of obesity may account for the association between
obesity and CKD. Indeed, obesity constitutes a complex syndrome involving metabolic traits and other
factors that may interact with other environmental factors, leading to an increased risk for developing
kidney disease. Clustering of these traits defines MetS, which has been reported to be consistently
associated with CKD in cross-sectional studies [17,18].
NAFLD has been recently found to be an additional feature of MetS, with the main underlying
cardiometabolic risk factors of the syndrome being abdominal obesity and insulin resistance [19,20].
Of note, insulin resistance is not only a metabolic determinant for the development of NAFLD but is
also a predictor of incident CKD [21,22]. In addition, atherogenic dyslipidemia and type 2 diabetes are
established risk factors for CKD [23,24]. As a consequence, many authors have concluded that NAFLD
may have a pathogenic role in the development of CKD. The results of a recent meta-analysis have
shown that (1) there is a positive relationship between NAFLD and an increased risk of CKD in adults;
(2) the severity of liver disease is associated with an increased risk and severity of CKD; and (3) these
relationships are maintained even after taking account of the well-known risk factors for CKD, and are
independent of whole body/abdominal obesity and insulin resistance [8].
In our study, we investigated the influence of NAFLD on kidney function in a large pediatric
population. This is the first study to demonstrate that overweight/obese children with NAFLD
have a greater frequency of eGFR of <90 mL/min/1.73 m2 as well as of microalbuminuria than
overweight/obese children without NAFLD. Furthermore, in the small number of children with
biopsy-proven NAFLD we were able to show that the decline in renal function was greater in those
with NASH. It is important to point out that subjects with obesity represent a particular population
in whom early renal lesion consists of hyperfiltration. In fact, in line with previous studies [25–27],
one of the main findings of this study was that children with overweight/obesity compared to
normal-weight subjects had a higher prevalence of hyperfiltration, regardless of liver involvement.
Glomerular hyperfiltration is well-recognized as an early renal injury occurring in a number of clinical
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conditions, including diabetes, hypertension, and obesity [28]. Hyperfiltration is hypothesized to
be a precursor of intraglomerular hypertension responsible for albuminuria. GFR then declines
progressively as albuminuria increases which may cause, in the long run, end-stage renal failure [28].
Thus, in obese patients with NAFLD, we should pay attention for minor impairment on renal function,
since hyperfiltration may mask a pathological decline in renal function.
The most plausible explanation for our findings is that the renal abnormalities in
overweight/obese children with NAFLD may reflect the coexistence of underlying metabolic risk
factors including higher BP, more dyslipidemia, and more insulin resistance compared to children
without liver involvement. However, because in our study the presence of NAFLD remained
significantly associated with decreased eGFR and/or microalbuminuria after taking account of
traditional metabolic traits, we cannot rule out the possibility that NAFLD might at least in
part contribute to the development of renal dysfunction independently of shared cardiometabolic
risk factors.
The strength of our study includes a large sample size and an extensive and complete analysis
of metabolic variables. Nonetheless, some limitations require consideration. First, the cross-sectional
design of the study precludes the establishment of causal relationship between NAFLD and abnormal
kidney function. Second, we used an estimated GFR instead of a directly measured GFR to define
renal function. The gold standard technique is clearance of inulin, but practical problems limit the
application of this cumbersome methodology in children because of the necessity for steady-state
infusion, and a urine sampling with a bladder catheter. Other tests for determining GFR are clearance
of alternative exogenous markers such as iothalamate, which are also complex and difficult to do in
routine clinical practice. Recent studies in children have reported current eGFR creatinine- and/or
cystatin C-based equations to be reliable methods to assess kidney function, with some variations
depending on the GFR ranges and the BMI classes [29–31]. The updated Schwartz formula has been
shown to be accurate for estimating GFR when compared to inulin clearance as well as to iothalamate
clearance in children and adolescents, with a wide range of renal function [29,30]. Moreover, obesity
has not been found to affect GFR as estimated by Schwartz formula [31]. Finally, we measured
creatinine concentration by kinetic colorimetric compensated technique, whereas in the updated
Schwartz formula, it was determined by an enzymatic method. The two methods, however, are highly
correlated [29].
In conclusion, our present study suggests that obese children with NAFLD are at risk for early
renal dysfunction. Recognition of this abnormality in the young may be important because treatment
to reverse the process is most likely to be effective if applied earlier in the disease process.
4. Materials and Methods
4.1. Study Subjects
This observational cross-sectional study included 596 children and adolescents with
overweight/obesity who were consecutively recruited at the outpatient Clinics (Hepatology, Lipid
and Nutrition) of the Department of Pediatrics, Sapienza University of Rome, Italy, between 2007 and
2015. Two hundred and sixty eight subjects met the criteria for the diagnosis of NAFLD (i.e., hepatic
fat fraction (HFF) ě5% on magnetic resonance imaging (MRI)) [32]. In all enrollees, hepatic virus
infections (hepatitis A–E and G, cytomegalovirus, and Epstein–Barr virus), autoimmune hepatitis,
metabolic liver disease, α-1-antitrypsin deficiency, cystic fibrosis, Wilson’s disease, hemochromatosis,
and celiac disease were excluded using appropriate tests [6,7]. In 41 of the NAFLD patients, due to
persistent elevations in ALT concentrations, a liver biopsy was performed. The other 328 participants
had HFF < 5% on MRI, normal levels of aminotransferases, and no evidence of chronic liver diseases
(see above). Use of hepatotoxic drugs, as well as a history of type 1 or 2 diabetes, smoking and chronic
alcohol intake were also exclusion criteria. None of the subjects had a history or known clinical,
laboratory, and imaging signs of renal disease.
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The study also included a total of 130 apparently healthy normal-weight school students drawn
from four randomly selected schools in the Rome area. All students were invited to take part in a pilot
study whose objective was the prevention of cardiovascular disease in childhood. Eligibility criteria
included age- and gender-specific BMI; no history of renal and liver diseases as well as of alcohol
consumption and smoking; normal liver ultrasound, and normal biochemical values.
All study subjects had a complete physical examination, as reported in detail elsewhere [5,6].
The degree of obesity was quantified using Cole’s least mean-square method, which normalizes the
skewed distribution of BMI and expresses BMI as SD score [33].
The study protocol was reviewed and approved by the Ethics Committee of Policlinico Umberto I
Hospital, Rome, Italy. Written informed consent was obtained from the parents, or guardians of the
children included in this study, in accordance with principles of Helsinki Declaration.
4.2. Laboratory Mmeasurements
Blood samples were taken from all study subjects, after an overnight fast, for estimation of
glucose, insulin, urea nitrogen, creatinine, uric acid, total cholesterol, HDL-C, triglycerides, ALT,
AST, and gamma-glutamyl transferase. An oral glucose tolerance test was performed for all
overweight/obese children using 1.75 g/kg of glucose up to a maximum of 75 g. Two-hour post-load
glucose and insulin were analyzed. Insulin resistance was calculated by the HOMA-IR. Insulin
sensitivity was calculated by the WBISI with reduced time points according to the following formula:
10,000/
‘
(fasting glucose ˆ fasting insulin ˆ 2 h post-load glucose ˆ 2 h post-load insulin) [34].
All analyses were performed on COBAS 6000 (Roche Diagnostics, Risch-Rotkreuz, Switzerland).
Creatinine concentrations were measured by the kinetic colorimetric compensated Jaffé method using
the Roche platform and the CREJ2–creatinine Jaffé Gen.2 assay (Roche Diagnostics, Identification
number, 0769282), which was isotope-dilution mass spectrometry standardized, traceable to National
Institute of Standards and Technology creatinine standard reference material (SRM 914 and SRM 967).
Urinary albumin was determined on 24 h urine collections by the turbidimetric immunoassay ALBT2
(Roche Diagnostics, Identification number, 0767433).
eGFR was calculated using the updated Schwartz formula: 0.413 ˆ height (cm)/serum creatinine
(mg/dL) [35].
4.3. Liver Ultrasound Eexamination and Magnetic Resonance Imaging
Liver ultrasound was performed by a single operator. Hepatic steatosis was diagnosed on the
basis of the following features: a diffuse increase in echogenicity (a bright liver), liver to kidney contrast,
deep beam attenuation, vascular blurring, and loss of definition of the diaphragm [36]. The amount
of HFF was measured by MRI using the two-point Dixon method as modified by Fishbein [37],
as previously described and validated [32,38].
4.4. Liver Biopsy
Liver biopsy was performed in 41 subjects because of persistent elevation in ALT. The clinical
indication for biopsy was either to assess the presence of nonalcoholic steatohepatitis (NASH) or
to determine the presence of other independent or competing liver diseases. The main histologic
features of NAFLD were scored using the NASH Clinical Research Network criteria [39]. Biopsies were
categorized into not-NASH and definite-NASH.
4.5. Definitions
Overweight and obesity were defined according to age- and gender-specific cut-off points of BMI
defined by the International Obesity Task Force criteria as proposed by Cole et al. [33]. Elevated BP was
defined as systolic or diastolic BP ě 90th percentile for age, gender, and height [40]. Impaired fasting
glucose was defined as glucose ě5.6 mmol/L. High waist circumference (WC), high triglycerides,
and low HDL-C were defined using the cut-off proposed by Cook et al. [41]. Insulin resistance
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was defined by 90th percentile of HOMA-IR for age and gender in our population of healthy
normal-weight children. Abnormal albuminuria was defined as a 24-h urinary albumin excretion
rate ě30 mg (i.e., microalbuminuria was diagnosed if the 24-h albumin excretion rate was 30–299 mg
and macroalbuminuria if the 24-h albumin excretion rate was ě300 mg) [42]. As recommended by
Kidney Disease Improving Global Outcomes (KDIGO) guidelines, eGFR categories were classified
as follows: normal or high ě90 mL/min/1.73 m2; mildly decreased, 60–89; mildly to moderately
decreased, 45–59; moderately to severely decreased, 30–44; severely decreased, 15–29; and kidney
failure <15 [42]. In the absence of an agreement in the literature, we defined glomerular hyperfiltration
as eGFR > 95th percentile of that observed in our population of healthy normal-weight subjects
(i.e., eGFR > 139 mL/min/1.73 m2).
4.6. Statistical Analysis
Statistical analyses were performed using the SPSS package (version 22.0, SPSS Inc., Chicago,
IL, USA). Data are reported as means and standard deviations for normally distributed variables,
or as median and interquartile range for non-normally distributed variables. Differences between
study groups in quantitative variables were evaluated by one-way analysis of variance (ANOVA)
or Kruskal–Wallis test, as appropriate. Proportions were compared by the chi square test.
Logistic regression analysis was used to assess the independent association of NAFLD with abnormal
kidney function, after adjustment for age, gender, pubertal status, BMI-SD score, WC, hypertension,
low HDL-C values, elevated triglycerides, and glucose impairment.
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